David V Sheehan1, Kazuyuki Nakagome2, Yuko Asami3, Elizabeth A Pappadopulos4, Matthieu Boucher5. 1. University of South Florida College of Medicine, Tampa, FL, USA. Electronic address: dsheehan@health.usf.edu. 2. National Center of Neurology and Psychiatry, Tokyo, Japan. 3. Pfizer Japan Inc, Tokyo, Japan. 4. Pfizer Inc, New York, NY, USA. 5. Pfizer Canada Inc. Kirkland, Quebec, Canada.
Abstract
BACKGROUND: Functional impairment contributes to significant disability and economic burden in major depressive disorder (MDD). Treatment response is measured by improvement in depressive symptoms, but functional improvement often lags behind symptomatic improvement. Residual deficits are associated with relapse of depressive symptoms. METHODS: A literature search was conducted using the following terms: "major depressive disorder," "functional impairment," "functional outcomes," "recovery of function," "treatment outcome," "outcome assessment," "social functioning," "presenteeism," "absenteeism," "psychiatric status rating scales," and "quality of life." Search limits included publication date (January 1, 1995 to August 31, 2016), English language, and human clinical trials. Controlled, acute-phase, nonrecurrent MDD treatment studies in adults were included if a functional outcome was measured at baseline and endpoint. RESULTS: The qualitative analysis included 35 controlled studies. The Sheehan Disability Scale was the most commonly used functional assessment. Antidepressant treatments significantly improved functional outcomes. Early treatment response predicted functional improvement, while baseline disease severity did not. LIMITATIONS: Clinical studies utilized various methodologies and assessments for functional impairment, and were not standardized or adequately powered. CONCLUSIONS: The lack of synchronicity between symptomatic and functional improvement highlights an unmet need for MDD. Treatment guided by routine monitoring of symptoms and functionality may minimize residual functional impairments.
BACKGROUND: Functional impairment contributes to significant disability and economic burden in major depressive disorder (MDD). Treatment response is measured by improvement in depressive symptoms, but functional improvement often lags behind symptomatic improvement. Residual deficits are associated with relapse of depressive symptoms. METHODS: A literature search was conducted using the following terms: "major depressive disorder," "functional impairment," "functional outcomes," "recovery of function," "treatment outcome," "outcome assessment," "social functioning," "presenteeism," "absenteeism," "psychiatric status rating scales," and "quality of life." Search limits included publication date (January 1, 1995 to August 31, 2016), English language, and human clinical trials. Controlled, acute-phase, nonrecurrent MDD treatment studies in adults were included if a functional outcome was measured at baseline and endpoint. RESULTS: The qualitative analysis included 35 controlled studies. The Sheehan Disability Scale was the most commonly used functional assessment. Antidepressant treatments significantly improved functional outcomes. Early treatment response predicted functional improvement, while baseline disease severity did not. LIMITATIONS: Clinical studies utilized various methodologies and assessments for functional impairment, and were not standardized or adequately powered. CONCLUSIONS: The lack of synchronicity between symptomatic and functional improvement highlights an unmet need for MDD. Treatment guided by routine monitoring of symptoms and functionality may minimize residual functional impairments.
Authors: Zindel V Segal; Sona Dimidjian; Arne Beck; Jennifer M Boggs; Rachel Vanderkruik; Christina A Metcalf; Robert Gallop; Jennifer N Felder; Joseph Levy Journal: JAMA Psychiatry Date: 2020-06-01 Impact factor: 21.596
Authors: Taylor A James; Samuel Weiss-Cowie; Zachary Hopton; Paul Verhaeghen; Vonetta M Dotson; Audrey Duarte Journal: Psychol Bull Date: 2021-11 Impact factor: 23.027
Authors: Emmanuelle Weiller; Catherine Weiss; Christopher P Watling; Christopher Edge; Mary Hobart; Hans Eriksson; Maurizio Fava Journal: Neuropsychiatr Dis Treat Date: 2017-12-29 Impact factor: 2.570